Italia markets open in 8 hours 18 minutes

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
4,5000+0,5800 (+14,80%)
Alla chiusura: 04:00PM EDT
4,5000 0,00 (0,00%)
Dopo ore: 06:38PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,9200
Aperto4,0000
Denaro4,4900 x 1300
Lettera4,5200 x 400
Min-Max giorno3,9300 - 4,5100
Intervallo di 52 settimane1,1500 - 6,2300
Volume5.765.132
Media Volume2.366.054
Capitalizzazione404,856M
Beta (5 anni mensile)2,91
Rapporto PE (ttm)N/D
EPS (ttm)-0,1300
Prossima data utili30 apr 2024 - 06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A9,00
  • GlobeNewswire

    Aquestive Therapeutics Provides Business Update

    Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual FilmReaffirms fourth quarter 2023 Anaphylm pivotal Phase 3 study start and first quarter 2024 topline data readoutOutlines expected remaining activities for Anaphylm program prior to NDA submissionIndicates FDA review of Libervant™ (diazepam) Buccal Film NDA on track with no open questions Anticipates increasing 2023 revenue and decreasing non-GAAP adjusted EBITDA loss guidance in upcoming earnin

  • GlobeNewswire

    Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

    WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on the development timeline and pathway for its oral epinephrine product candidate, Anaphylm™. As previously disclosed, Aquestive submitted its revised protocol for the proposed pivotal PK clinical trial to the Food an

  • GlobeNewswire

    Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

    FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients between two and five years of agePrescription Drug User Fee Act (PDUFA) target goal date set for April 28, 2024 WARREN, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their live